Abstract
The world is facing a new pandemic caused by a novel beta coronavirus (COVID 19), which causes severe respiratory coronavirus syndrome (SARS-CoV-2). Unfortunately, there are currently no US Food and Drug Administration (FDA) approved medications for the treatment of COVID-19 patients. High mortality rates in frail patients is a notable feature of the virus registered since the onset of COVID-19 pandemic. Above all, elderly patients or those with underlying chronic illnesses and compromised immune system are most at risk (1). Thus, the consideration is that the possible coexistence, in the same individual, of a cancer diagnosis and a COVID-19 infection could generate a synergistic negative prognostic effect.
Lingua originale | English |
---|---|
Numero di pagine | 3 |
Rivista | Frontiers in Oncology |
Volume | 10 |
Stato di pubblicazione | Published - 2020 |
All Science Journal Classification (ASJC) codes
- ???subjectarea.asjc.2700.2730???
- ???subjectarea.asjc.1300.1306???